gms | German Medical Science

23rd Annual Meeting of the German Retina Society

German Retina Society

24.09. - 25.09.2010, Freiburg

Value of Superselective Ophthalmic Artery Chemotherapy with Melphahlan for Retinoblastoma

Meeting Abstract

Search Medline for

  • Markus Holdt - University Eye Clinic Essen
  • N. Bornfeld - University Eye Clinic Essen

German Retina Society. 23rd Annual Conference of the German Retina Society. Freiburg i. Br., 24.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. Doc10rg38

doi: 10.3205/10rg38, urn:nbn:de:0183-10rg387

This is the translated version of the article.
The original version can be found at:

Published: September 21, 2010

© 2010 Holdt et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Background: Retinoblastoma requires multiple therapeutical approaches concerning Stage and Laterality. The Superselective Ophthalmic Artery Chemotherapy via the Femoral Artery is a recent development with a controversial discussion.

Methods: We report about our experiences of 7 interventions of 6 patients. We overview the possible indications according to the stage of disease.

Results: 4 of 7 planned interventions with 3 mg Melphalan succeeded. 3 patients have been treated one time, one patient two times. Because of anatomical reasons the intervention failed in three cases. The tumours showed a good response. Transient side effects are limited to neutropenia, lid edema, supraorbital hyperemia and loss of lashes.

Conclusions: Superselective Ophthalmic Artery Chemotherapy with Melphalan depicts a promising approach. Longtime benefit and complications couldn’t be valued right now. In a well circumscribed manner, this procedure delivers an important option: 1. Bilateral retinoblastoma with relapse after established globe preserving therapies to prevent the enucleation. 2. Unilateral retinoblastom with a lower or moderate stage of disease. This opportunity can be discussed as a possible more gentle alternative comparing to systemic chemoreduction following focal treatment.